Take a low-calorie diet and exercise regularly to maintain weight loss
Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status
As mentioned previously, more research is needed to confirm these findings, but with the above studies to consider, it seems that attitudes on the potential benefits of Metformin are nothing if not optimistic
These effects make GLP-1 a powerful tool in managing weight and blood sugar levels, which is why it has become a focal point in the development of medications for diabetes and obesity
Along with protein intake, strength training is the most effective way to preserve lean muscle mass while losing weight
